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ABSTRACT: Human milk oligosaccharides (HMOs) play a key role in
shaping and maintaining a healthy infant gut microbiota. This article
demonstrates the potential of combining recent advances in glycomics
and genomics to correlate abundances of fecal microbes and fecal
HMOs. Serial fecal specimens from two healthy breast-fed infants were
analyzed by bacterial DNA sequencing to characterize the microbiota
and by mass spectrometry to determine abundances of specific HMOs
that passed through the intestinal tract without being consumed by the
luminal bacteria. In both infants, the fecal bacterial population shifted
from non-HMO-consuming microbes to HMO-consuming bacteria
during the first few weeks of life. An initial rise in fecal HMOs
corresponded with bacterial populations composed primarily of non-
HMO-consuming Enterobacteriaceae and Staphylococcaeae. This was
followed by decreases in fecal HMOs as the proportion of HMO-
consuming Bacteroidaceae and Bifidobacteriaceae increased. Analysis of
HMO structures with isomer differentiation revealed that HMO
consumption is highly structure-specific, with unique isomers being
consumed and others passing through the gut unaltered. These results represent a proof-of-concept and are consistent with the
highly selective, prebiotic effect of HMOs in shaping the gut microbiota in the first weeks of life. The analysis of selective fecal
bacterial substrates as a measure of alterations in the gut microbiota may be a potential marker of dysbiosis.
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■ INTRODUCTION
Breast milk, the sole source of nourishment for newborns, has
been under intense selective pressure over millions of years of
evolution to meet the infant’s needs to grow and survive.1,2
Interestingly, the third most abundant chemical component class
in human milk after lactose and lipids, human milk
oligosaccharides (HMOs), is both non-nutritive and non-
digestible.3 HMOs play a key role in creating and maintaining
a healthy infant gut microbiota through two established
mechanisms. First, HMOs have prebiotic effects (promoting
growth of beneficial bacteria such as Bifidobacterium and
Lactobacillus).4 Recent metagenomic studies have confirmed
that bifidobacteria are enriched in the intestines of healthy breast
fed infants.5 In vitro studies provide a reason for the prevalence of
bifidobacterial and even bacteroides species: they selectively
consume HMOs.6,7 A number of studies have characterized the
enzymes in bifidobacteria that specifically degrade HMOs
(reviewed in ref 8).
Second, HMOs compete for specific pathogen binding with
sites in the infant gut.9 Free HMOs and conjugated cell surface
glycoforms are synthesized by similar glycosyltransferases and
thus have common epitopes. Ingested HMOs can thus interact
with enterocyte surface molecules, limiting binding to these sites
by viruses such as HIV10 and rotavirus.11 In addition, because
HMOs are also unbound, they can serve as free analogues of
pathogen host receptors. Instead of binding to cell surface
glycoproteins or glycolipids, pathogens bind to HMOs. HMOs
therefore act as decoys and protect infants from infectious
diseases.9 Anti-adhesive activity of free HMOs has been
described for Vibrio cholerae,12 Salmonella fyris,12 enteropatho-
genic12 and enterotoxigenic13 Escherichia coli, Streptococcus
pneumoniae,14 and caliciviruses.13 The large diversity of HMO
structures suggests multiple functions.15 Separated HMO
fractions have been shown to have differing activities. For
instance, fucosylated HMOs inhibit the binding of Campylo-
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bactor jejuni to intestinal cells,16 whereas sialylated HMOs block
the adhesion of E. coli to human erythrocytes.17
The functions of HMOs are related to their specific structures;
however, identifying and quantifying those structures has been a
major challenge in HMO analysis. HMOs can have diverse and
complicated structures even though they commonly share a
lactose core consisting of glucose and galactose linked via a β-1,4-
linkage.18 Functional studies to date have involved either a
limited number of structures or little or no structural
information.
The benefits of breast feeding include the long-term health
implications of a well-established, specific, and protective
microbiota. Recent advances in glycomic analysis and genomic
sequencing have allowed us to observe the correlation between
HMO consumption and gut microbiota populations. In this
study, we demonstrate two examples of direct correlation
between the abundances of HMOs in feces and the composition
of the infant fecal microbiota as proof-of-concept. HMOs from
fecal samples of breast-fed infants were analyzed using advanced
separation and mass spectrometry methods that allow
quantitation of specific structures. Microbial populations were
characterized by next-generation sequencing of 16S rDNA
amplicons, specific qPCR, and Bifidobacterium species-specific
terminal restriction fragment length polymorphism (Bif-
TRFLP). The observed shift in the gut microbiota of these two
healthy infants from a non-HMO-consuming population into a
more saccharolytic microbiota with a corresponding decrease in
fecal HMO intensities supports more extensive analyses of larger
populations.
■ METHODS
Sample Collection and Handling
The study was approved by the Institutional Review Board at UC
Davis (protocol no. 200715509-4), and informed consent was
obtained from the parents of infants prior to participation. The
infants included were born vaginally at term and were not treated
with antibiotics during the study period. Infant A received
exclusive breast milk feeding. Infant B had formula supplemen-
tation for 4 days right after birth, from days 2 to 6, and then was
solely breast fed. Details of the mothers’ diet and health status
were not collected as part of this study.
Feces samples were collected from two full-term infants as
follows: twice a week for the first month, twice a month in the
second month, and once or twice a month thereafter. The
samples were stored at −80 °C prior to analysis. Samples were
thawed, reconstituted with water, and homogenized prior to
analysis. Homogenate was left in the shaker at 4 °C overnight.
The mixture then was centrifuged at 4000g for 30 min at 4 °C.
Isolation, Reduction, and Purification of HMOs from Fecal
Samples
Crude HMOs were isolated and purified from extracted feces
through a series of liquid- and solid-phase extractions, as
described previously.19,20 Briefly, four volumes of chloroform/
methanol (2:1 v/v) were added to the decanted liquid, and the
mixture was centrifuged at 4000g for 30 min at 4 °C. The upper
layer was carefully transferred. Two volumes of ethanol were
added, and the mixture was left at 4 °C overnight and then
centrifuged for 30 min at 4 °C. The supernatant solution was
evaporated to dryness using a centrifugal evaporator (Savant AES
2010).
HMOs were reduced to alditol form by adding sodium
borohydride and incubating at 65 °C for 1 h, purified by solid-
phase extraction using C8 and graphitized carbon columns,20 and
evaporated to dryness. The sample was reconstituted in
nanopure water prior to mass spectrometry.
Mass Spectrometric Analysis and Identification of Fecal
HMOs
Oligosaccharides were profiled using matrix-assisted laser
desorption/ionization Fourier transform ion cyclotron reso-
nance mass spectrometry (MALDI FT-ICR MS, Agilent,
formerly Varian, Palo Alto, CA, equipped with an external
ProMALDI source) and nano-high-performance liquid chip/
time-of-flight (nano-HPLC-Chip/TOF, Agilent 6200) MS, as
described previously.19,20 For MALDI FT-ICR MS experiments,
2,5-dihydroxy-benzoic acid (DHB) was used as matrix (5 mg/
100 μL in 50:50 ACN/H2O) and sodium chloride (0.01 M in
50:50 ACN/H2O)was used as cation dopant. The precursor ions
were detected primarily as [M + Na]+ ions in the positive
ionization mode. Identification of HMO compositions was done
based on accurate masses using Glycan Finder software (written
in-house in Igor Pro 5.04B, Wavemetrics), which filters
experimental accurate masses to a specified mass tolerance (set
at 20 ppm) based on accurate masses of theoretical
oligosaccharides.
The nano-HLPC-Chip/TOF MS experiments, as described
previously,19,20 were performed using a porous graphitized
carbon HPLC microchip with a 40 nL enrichment column and
43 × 0.075 mm i.d./5 μm pore size analytical column. Separation
was achieved using a binary gradient solvent system with A (3%
ACN in 0.1% formic acid solution) and B (90% ACN in 0.1%
formic acid solution). The chip column was equilibrated and
eluted at a flow rate of 0.4 μL for nanopump and 4 μL for capillary
pump. The gradient ran for 65 min and was programmed as
follows: 2.5−20 min, 0−16% B; 20−30 min, 16−44% B; 30−35
min, B increased to 100%; 35−45 min, continue at 100% B; and
45−65 min, 0% B to allow equilibration of the column prior to
the next sample injection. Data were acquired in the mass range
of m/z 200−3000 using electrospray ionization (ESI) in the
positive ionization mode. Deconvoluted peaks were extracted
using the molecular feature of the Agilent Mass Hunter software
at 20 ppm error. The resulting peak list was further analyzed
using the LC−MS Searcher software21 (in-house, written in
Java), which assigns structures to a peak based on retention time
and accurate mass. LC−MS Searcher uses a library of 45 neutral
HMOs and 30 acidic HMOs characterized using exoglycosidases
and MS/MS by Wu et al.22,23 Around 2000 spectra are inputted
in the program per run, and with the HMO library, the LC−MS
Searcher software identifies HMOs from all of the scans based on
retention times and m/z values. It then outputs intensities,
structures, and deuterium/hydrogen (D/H) ratios of said
HMOs. This library approach allows for separation of isomeric
species and identification of individual structures based primarily
on accurate masses and reproducible retention times, since
extensive confirmation of HMOs by MS/MS and exoglycosi-
dases were done previously.22,23
Quantification of Milk Oligosaccharides Using
Deuterium-Labeled Internal Standard
Deuterium-labeled internal standards were used for the relative
quantification of HMOs using MALDI FT-ICRMS, as described
previously.20 This method gives a relative standard deviation of
less than 15% and allows for a more linear quantitation over a
larger dynamic range.20 Briefly, pooled HMOs isolated frommilk
of several donor mothers were reduced using sodium
borodeuteride, purified by graphitized carbon solid-phase
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extraction, and used as reference solution. Both the deuterated
reference solution and sample solution were spotted as one
sample onto the MALDI plate and analyzed by MALDI FT-ICR
MS in the positive mode (n = 3). The ratio of sample reduced by
NaBH4 and standard reduced by NaBD4 (H/D ratio) was
calculated using Microsoft Excel using the formula described
below.
H/D ratios were used for quantitation as described by
Ninonuevo et al.24
=
−
m
n mq p
H
D ( / )
where m and n are the experimental intensities of A
(monoisotopic peak) and A + 1, respectively, and p and q are
calculated intensities of A and A + 1, respectively.
To compute the temporal changes in the H to D ratios across a
set of samples, a reference sample is set and is used to compare
with all the other samples
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To quantitate oligosaccharide to the isomer level, both the
deuterated reference solution and sample solution were also
injected into the nano-HPLC-Chip/TOF MS. H/D ratios were
calculated using LC−MS Searcher21 (the program outputs D/H
ratios; we took the reciprocal) and verified manually using
Microsoft Excel.
Bacterial DNA Extraction
Bacterial genomic DNA was extracted from fecal samples in
order to analyze the infant gut microbial populations as
previously described with a few modifications.25 Briefly, 200
mg of stool was resuspended 1:10 in ice-cold phosphate buffer
solution (PBS) and centrifuged (8000g for 5 min at room
temperature); then, the supernatant was decanted. This rinse was
repeated twice, and the fecal pellet was resuspended in 200 μL of
lysis buffer (2 mM EDTA, 1.2% TritonX-100, 20 mM Tris-HCl,
pH 8.0) with freshly added 40 mg/mL lysozyme. The solution
was incubated at 37 °C for 30 min. Buffer ASL from QIAamp
DNA Stool Mini Kit (Qiagen, Valencia, CA) was added to equal
2.0 mL, and the sample was then vortexed until it was thoroughly
mixed. Samples were then homogenized by bead-beating in a
FastPrep-24 instrument (MP Biomedicals, Solon, OH) for 2 min
at 6.5 m/s. Homogenate was incubated for 5 min at 95 °C,
vortexed, and centrifuged at 13 000g for 1 min to pellet stool
particles. 1.2 mL of the supernatant was used to purify DNA with
the Qiagen Stool Mini Kit according to the manufacturer’s
instructions.
Pyrosequencing
Preparation of fecal DNA samples for pyrosequencing was
carried out as previously described25 by the Core for Applied
Genomics and Ecology (CAGE, University of Nebraska). The
V1−V3 region of the 16S rRNA gene was PCR amplified using
bar-coded universal primers with Roche-454 A or B Titanium
adapter sequences, shown in italics, B-8F (5′-CCTATCC-
CCTGTGTGCCTTGGCAGTCTCAGAGAGTTTGATC-
MTGGCTCAG-3′) and A-518R (5′-CCATCTCATCC-
CTGCGTGTCTCCGACTCAGNNNNNNNNATTACCGCG-
GCTGCTGG-3′), where the N represents the 8 base barcode
sequence unique to each sample. To ensure the representation of
Bifidobacteria, Bifidobacteria-specific primer B-8Fbif (5′-
CCTATCCCCTGTGTGCCTTGGCAGTCTCAGAGG-
GTTCGATTCTGGCTCAG-3′) was mixed with the 8F
universal primer, which has a 3 base pair mismatch, at a
concentration of 4:1. The PCR mixture and amplification
conditions were as previously described.25 Sequencing was
performed using the 454 Roche sequencing primer kit from the A
end and carried out using the standard protocol on a Roche
Genome Sequencer GS-FLX.
Illumina Sequencing
Samples were prepared for sequencing as previously described26
with some variations. The V4 region of the 16S rRNA gene was
PCR amplified using universal barcoded primers with Illumina
sequencing adapters, shown in italics, the N represents the 8 bp
barcode sequence unique to each sample, and the linker is in
bold, V4F (5′-AATGATACGGCGACCACCGAGATCTA-
CACTCTTTCCCTACACGACGCTCTTCCGATCTNN-
NNNNNNGTGTGCCAGCMGCCGCGGTAA-3′) and
V4Rev (5 ′-CAAGCAGAAGACGGCATACGAGATCG-
GTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTCCG-
GACTACHVGGGTWTCTAAT-3′). PCR reactions contained
12.5 μL of 2× GoTaq Green Master Mix (Promega, Madison,
WI), 1.0 μL of 25 mMMgCl2, 8.5 μL of water, 0.5 μL of forward
and reverse primers (10 μM final concentration), and 2.0 μL of
genomic DNA. PCR amplification was carried out in triplicate
with conditions as previously described.26 Amplicons were
combined and cleaned using the QIAquick 96 PCR Purification
Kit (Qiagen, Valencia, CA). AmpliconDNA concentrations were
quantified using the Quant-iT PicoGreen dsDNA Kit in 96-well
microplates, and fluorescence detection, composite sample
mixture, and gel purification were carried out as previously
described.26 The sample was sent to the University of California
DNA Technologies Core Facility for sequencing on an Illumina
Genome Analyzer II sequencing platform.
Sequence Analysis
TheQIIME software package (version 1.4.0) was used to analyze
the results of both the pyrosequencing and Illumina sequencing
runs.27 V1−V3 16S rRNA gene sequences from pyrosequencing
reads were removed from analysis if they were <200 bp in length,
contained >3 ambiguous bases, had a mean quality score <25,
contained a homopolymer run greater than 6 nt, or did not
contain a primer or a barcode sequence. Similar sequences were
clustered into operational taxonomic units (OTUs) with
UCLUST software28 and minimum identity of 97%. The most
abundant sequence was chosen to represent each OTU.
Taxonomy was assigned to each OTU with the Ribosomal
Database Project (RDP) classifier,29 with a minimum support
threshold of 80% and the RDP taxonomic nomenclature. OTU
representatives were aligned against the Greengenes core set30
with PyNAST software31 with a minimum alignment length of
150 bp and a minimum identity of 75%. A phylogenetic tree was
inferred using FastTree algorithm.32
Illumina V4 16S rRNA gene sequences were demultiplexed
and quality-filtered using the QIIME software package as well.27
Reads were truncated after a maximum number of 3 consecutive
low-quality scores. After quality trimming, reads were removed
from analysis if they were <60 bp and the number of ambiguous
bases was >3. OTU clustering, taxonomy assignment,
phylogenetic tree-building, and alignment were carried out as
stated above, with the exception that the minimum alignment
length was 75 bp. OTUs with sequences that numbered less than
0.01% of the total reads were filtered out to reduce noise in the
assignments.
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Community Comparisons and Statistics
Alpha rarefaction was performed using the observed species
metrics. Ten sampling repetitions were performed at each
sampling depth, without replacement. Beta diversity was
estimated by computing weighted and unweighted UniFrac
distances between samples.
Pearson product−moment correlation coefficients were
calculated in QIIME27 between the nano-HPLC-Chip/TOF
MS D/H ratios of individual HMO isomers normalized to
baseline intensity and the relative abundances of order-level
bacterial taxa. Only bacterial orders detected in at least three
samples per infant were included.
Real-Time Quantitative Polymerase Chain Reaction (qPCR)
SYBR green and TaqMan qPCR assays were performed on a
7500 Fast Real-Time PCR System (Applied Biosystems,
Carlsbad, CA) with primers specific for universal Bacteria,
Bacteroidales, and Bifidobacterium, and species-specific Bifidobac-
terium primers for B. longum group, B. adolescentis group, B.
catenulatum group, B. breve, and B. bifidum. SYBR green assays
contained 10 μL of 2× Takara Perfect Real Time master mix, 6
μL of water, 1 μL each of forward and reverse primers, and 2 μL
of genomic DNA. Genomic DNA was diluted 1:100 for Bacteria,
Bacteroidales, and Bifidobacterium assays. Cycling conditions
were as previously described (Supporting Information Table 1).
Bifidobacterium TaqMan qPCR assays contained 12.5 μL of 2×
TaqMan Universal PCR master mix (Applied Biosystems), 2.5
μL each of forward and reverse primers, TaqMan probe, 3.75 μL
of water, and 2.5 μL of diluted genomic DNA. B. longum group
TaqMan assays contained 10 μL 2× TaqMan Universal PCR
master mix (Applied Biosystems), 1 μL each forward and reverse
primers and TaqMan probe, 5 μLwater, and 2 μL genomic DNA.
Reaction conditions and primer concentrations were as
described in Supporting Information Table 1. All reactions
were carried out in triplicate with a nontemplate control.
Bif idobacterium Species-Specific Terminal Restriction
Fragment Length Polymorphism (Bif-TRFLP)
Bifidobacterium genus-specific primers (NBIF389, 5′-
GCCTTCGGGTTGTAAAC; and NBIF1018R, 5′-GACCA-
TGCACCCCTGTG-3′) were designed targeting a consensus
alignment of 16S rRNA genes from all Bifidobacterium sequences
deposited in the ribosomal database project (RDP) database33,34
aligned using ClustalX.35 Primer specificity and taxonomic
coverage were determined using PrimerProspector,26 checking
against a representative subset of the greengenes 16S rRNA
database filtered at 97% identity.30 Samples were amplified by
PCR in 50 μL reactions containing 5−100 ng of DNA template,
25 μL of 2× Promega GoTaq Green Master Mix (Promega,
Madison, WI), 1 mM of MgCl2, and 2 pmol of each primer. Each
PCR was performed in triplicate, and the products combined
prior to purification. The PCR conditions consisted of an initial
denaturation at 95 °C for 2 min, followed by 30 cycles of
denaturation at 95 °C for 1min, annealing at 51 °C for 1min, and
extension at 72 °C for 2 min, with a final extension at 72 °C for 5
min. Amplicons were digested using AluI and HaeIII following
the manufacturers’ instructions for each enzyme. The digested
DNA was submitted to the UC Davis College of Biological
Sciences Sequencing Facility for fragment analysis. Traces were
visualized using the program Peak Scanner v1.0 (Applied
Biosystems) using a baseline detection value of 10 fluorescence
units. Peak filtration and clustering were performed with R
software using the IBEST script suite.36 OTU picking was based
on an in silico digest database generated by the virtual digest tool
from MiCA37 of good-quality 16S rRNA gene sequences
compiled by the Ribosomal Database Project Release 10,33,34
allowing up to 3 nucleotide mismatches within 15 bp of the 5′
terminus of the forward primer.
■ RESULTS
Fecal Profiling of Infant A
Fecal glycoprofiles and microbial profiles were obtained for
weeks 0, 1, 2, and 13. Previous results have shown that the glycan
composition is relatively constant for mature milk over a 6month
period.38 The amount of HMO ingested increases as milk
consumption increases over the first several weeks of life. Figure
1 shows the fecal oligosaccharide compositions (analyzed by
MALDI FT-ICR MS) and bacterial populations (analyzed by
16S rDNA pyrosequencing) of Infant A at the four time points.
Oligosaccharides are listed in the legend as nominal masses of the
reduced glycan. Corresponding monoisotopic masses and
compositions of the nominal masses in Figure 1 are shown in
Table 1. The table also showsmonoisotopic masses of [M+Na]+
ion, the commonly observed ion in MALDI FT-ICR MS. Exact
masses and elemental compositions were calculated using the
NIST Glyco Mass Calculator (De Leoz and Stein, http://
c h e m d a t a . n i s t . g o v / d o k u w i k i / d o k u . p h p ? i d =
chemdata:glycocalc).
All HMOs were normalized to week 0. The graph in week 0
(Figure 1A) should not be interpreted as each composition
having the same abundances. Each bar in the glycoprofile
corresponds to a specific oligosaccharide composition. Each
composition is composed of several isomers, as discussed in
greater detail below. Infant A shows a general increase of all fecal
HMOs from week 0 to week 1. At week 2, the amount of fecal
HMOs decreases to nearly the original level of week 0. At week
13, the fecal HMOs decrease to a fraction of the peak amount at
Figure 1. Changes in oligosaccharide intensities and bacterial
population in the feces of Infant A. (A) Percent change in H/D ratios
of HMOs in the feces of Infant A at weeks 0, 1, 2, and 13. Intensities were
obtained using MALDI FT-ICR MS with n = 3. H/D ratios were
normalized to week 0, set at 100%. Each bar represents an
oligosaccharide nominal mass. (B) Corresponding fecal bacterial
population of Infant A using 16S rDNA pyrosequencing.
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week 1. The decrease is not uniform; there are a number of
compositions that increase or are unchanged at week 13.
Order-level fecal populations are shown in Figure 2A, and
genus level, in Figure 2B. Multiplexed pyrosequencing and
Illumina sequencing of Infant A’s samples yielded 12 779 and
288 390 partial 16S rRNA gene sequence reads (mean length 492
and 143 bp), respectively. The mean number of reads per sample
was 5458 for pyrosequencing and 72 098 for Illumina. The
longer pyrosequencing reads allowed taxonomic identification
down to the genus level. The observed early predominance of
Streptococcus in the gut (Figure 1B) is consistent with previous
observations in breast fed infants.39 Marcobal et al.40 previously
demonstrated that tested species of streptococci consumed
HMO poorly or not at all. During the first week the fecal
oligosaccharides increase; we hypothesize that they are being
Table 1. Nominal Masses, Monoisotopic Masses, and Compositions of the Reduced HMOs Observed in Infants A and Ba
reduced glycan, M monosaccharide composition elemental composition [M + Na]+ ion
no. nominal mass monoisotopic mass Hex HexNAc Fuc NeuAc C H N O monoisotopic mass
1 709 709.2641 3 1 0 0 26 47 1 21 732.2533
2 855 855.3220 3 1 1 0 32 57 1 25 878.3112
3 1001 1001.3799 3 1 2 0 38 67 1 29 1024.3691
4 1074 1074.3963 4 2 0 0 40 70 2 31 1097.3855
5 1148 1147.4378 3 1 3 0 44 77 1 33 1170.4270
6 1221 1220.4542 4 2 1 0 46 80 2 35 1243.4434
7 1367 1366.5121 4 2 2 0 52 90 2 39 1389.5013
8 1440 1439.5285 5 3 0 0 54 93 3 41 1462.5177
9 1513 1512.5700 4 2 3 0 58 100 2 43 1535.5592
10 1586 1585.5864 5 3 1 0 60 103 3 45 1608.5756
11 1732 1731.6443 5 3 2 0 66 113 3 49 1754.63349
12 1805 1804.6607 6 4 0 0 68 116 4 51 1827.6499
13 1878 1877.7022 5 3 3 0 72 123 3 53 1900.6914
14 1951 1950.7186 6 4 1 0 74 126 4 55 1973.7078
15 2097 2096.7765 6 4 2 0 80 136 4 59 2119.7657
aThe monoisotopic masses of the [M + Na]+ precursor ion, the commonly observed ion in MALDI FT-ICR MS, are also shown. Hex, hexose;
HexNAc, N-acetylhexosamine; Fuc, fucose; NeuAc, N-acetylneuraminic acid.
Figure 2. Infant A microbial population changes over the first 13 weeks
based on next-generation sequencing. (A) Illumina and (B)
pyrosequencing profile of the V4 and the V1−V3 regions of the 16S
rRNA gene, respectively. The letters preceding the taxon are taxonomy
identifiers: p (phylum), c (class), o (order), f (family), and g (genus). Figure 3. Infant A microbial population changes over the first 13 weeks
based on qPCR and Bif-TRFLP analyses. qPCR of (A) Total bacteria,
Bifidobacteria, and Bacteroidales and (B) species-specific Bifidobacteria
populations; (C) Bif-TRFLP profile of the total bifidobacteria
community.
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provided by the mother but are not being consumed by the gut
microbes. The amount of oligosaccharides in feces peaks during
week 1; however, by week 2, there is a noticeable decrease in
intensities of HMOs corresponding with a small increase in fecal
Bacteroides sp. population (Figure 1A,B). Members of Bacteroides
and Bifidobacterium sp. are known to be strong consumers of
HMOs.7,8 Illumina sequencing shows a constant presence of low
levels of Bifidobacterium sp. in the first 3 weeks that is not
detected in the pyrosequencing results. Interestingly, by week 13,
the Bacteroides are replaced by Bifidobacterium sp., which
dominate the fecal bacterial population, and the levels of most
fecal HMO compositions have dropped dramatically.
Bifidobacterium-specific TRFLP and qPCR revealed a
succession of bifidobacterial species over time (Figure 3). B.
longum (includes two subspecies: B. longum subsp. longum and B.
longumssp. infantis) dominated these samples from weeks 0−13,
followed by an increase in B. adolescentis, B. bifidum, and B. breve
at weeks 13−26 (data not shown for weeks > 13).
The correlation of bifidobacterial growth with HMO
consumption was confirmed by calculating Pearson product−
moment correlation coefficients between normalized HMO D/
H ratios and the relative abundances of all order-level bacterial
taxa detected in at least three samples. Bifidobacteriales was the
only clade yielding a significant, negative correlation coefficient
with five HMOs, as shown in Table 2 (negative correlation
implying that as fecal bifidobacteria numbers increase, fecal
HMOs decrease, consistent with consumption of the HMOs).
Other bacteria demonstrate a significant, positive correlation,
indicating that as these microbes increased fecal HMOs
Table 2. Pearson Product−Moment Correlation between
Order-Level Taxa and HMO Abundance in Infant A
substrate prob r order
5130a 0.083 0.829 Lactobacillales
0.044 0.889 Bacillales
pLNH 0.008 0.963 Lactobacillales
IFLNH IIII 0.042 0.891 Clostridiales
MFLNH III 0.023 0.929 Enterobacteriales
MFLNH I 0.019 0.937 Lactobacillales
0.029 −0.916 Bifidobacteriales
IFLNH I 0.020 −0.933 Bifidobacteriales
LNT 0.041 0.894 Bacillales
0.046 −0.885 Bifidobacteriales
LnNH 0.014 −0.948 Bifidobacteriales
0.010 0.958 Lactobacillales
TFLNH 0.007 0.967 Other
5130a 0.014 0.949 Enterobacteriales
DFLNHc 0.012 0.954 Bacillales
LNH 0.032 0.909 Other
5230b 0.013 −0.951 Bifidobacteriales
5230a 0.044 0.888 Enterobacteriales
Figure 4. Changes in oligosaccharide intensities and bacterial
population in the feces of Infant B. (A) Percent change in H/D ratios
of HMOs in the feces of Infant B at weeks 0, 1, 2, and 14. Intensities were
obtained using MALDI FT-ICR MS in (+) ion mode with n = 3. H/D
ratios were normalized to week 0, set at 100%. Each bar represents an
oligosaccharide nominal mass. (B) Corresponding fecal bacterial
population of Infant B using 16S rDNA pyrosequencing.
Figure 5. Infant B microbial population changes over the first 14 weeks
of life based on next-generation sequencing. (A) Illumina and (B)
pyrosequencing profile of the V4 region and V1−V3 regions of the16S
rRNA gene, respectively.
Figure 6. InfantB microbial population changes over the first 14 weeks
of life based on qPCR analysis. qPCR of total bacteria, Bifidobacteria, and
Bacteroidales. * Bifidobacteria are below the limit of detection (1 × 104
16S rRNA genes per gram of stool).
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increased as well (consistent with lack of consumption of HMOs
by these bacteria, e.g., Enterobacteriales and Bacillales).
Fecal Profiling of Infant B
A second infant, Infant B, also shows development of a
saccharolytic microbiota. Figure 4A,B shows the glycoprofiles
(analyzed by MALDI FT-ICR MS) and bacterial populations
(analyzed by 16S rDNA pyrosequencing) over the infant’s first
14 weeks of life, respectively. We observe the fecal glycans to
increase dramatically from week 0 to week 1. Note that the y axis
in this figure is logarithmic and that the increases vary from 14-
fold to >1 million-fold. At week 2, there is little change in HMO
abundance in the feces, whereas at week 14, all of the measured
fecal HMOs have decreased (range 2-fold to 7000-fold higher
than baseline).
Multiplexed pyrosequencing and Illumina sequencing of
Infant B’s samples yielded 30 886 and 447 149 partial 16S
rRNA gene sequence reads, respectively. Order level fecal
populations are shown in Figure 5A, and genus level, in Figure
5B. The fecal bacterial population of this infant is initially
populated by nearly equal amounts of Enterobacteriaceae
(primarily Escherichia) and Bacteroides in week 0. By week 1,
Escherichia increases to be the dominant species as the amount of
Bacteroides decreases. At week 2, there is little change in either the
fecal microbiota or the fecal HMO composition. By week 14,
Bacteroidales dominate the population at 60%, and the
corresponding HMO fecal profile shows a decrease in intensity
of nearly all HMO compositions. These results correlate with our
previous in vitro observations that members of Bacteroidaceae,
e.g., Bacteroides fragilis, are consumers of HMOs.40
Interestingly, the drop in abundances of oligosaccharide for
Infant B is not as large as that for Infant A, where the majority of
bacteria at week 13 was Bifidobacterium sp. In vitro studies using
strains of both Bifidobacterium longum ssp. infantis (B. infantis)
and Bacteriodes thetaiotaomicron show that the former is a
stronger consumer of HMO than the latter.7,40 Bifidobacterium
sp. populations were low in Infant B, detectable by Illumina
sequencing (Figure 5A) but not by pyrosequencing (Figure 5B)
or qPCR (Figure 6). B. longum group was the only clade detected
by qPCR, although higher populations of B. bifidum were
detected by TRFLP as well as small populations of B. breve and B.
adolescentis (data not shown).
Isomer-Specific Temporal Changes in Fecal HMOs
A more extensive analysis supports the hypothesis of structure/
isomer-specific consumption of HMOs in the infants’ gut. The
Figure 7. H/D ratios of two isomeric groups of oligosaccharides in the fecal HMO profile of Infant A. H/D ratios were calculated using nano-HLPC
chip/TOFMS data. (A) Four isomers ofm/z 856 ([M +H]+, M = 855.3220, second bar from the left in each week in Figure 1A). (B) Three isomers of
m/z 538 ([M + 2H]2+, z = 2, M = 1074.3963, fourth bar from the left in Figure 1A). M = monoisotopic (neutral) mass.
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fecal profile of Infant A is dominated by Bifidobacterium spp. by
week 13 (Figure 1), and the fecal profile of Infant B is dominated
by Bacteroides spp. by week 14 (Figure 4). Although the patterns
are not equivalent, suggesting differential consumption, there are
some similarities in the consumption or nonconsumption of
certain HMOs.
In the fecal profile of Infant A, for example, a pentasaccharide
with monoisotopic mass of 855.3220 having the composition 3
hexose (galactose or glucose), 1 N-acetylglucosamine, and 1
fucose was found to have four isomers corresponding to the
common name lacto-N-fucopentaose: LNFP I, LNFP II, LNFP
III, and LNFP V. The fecal profiles are shown in Figure 7A as
quantified by the H/D ratio using nano-HLPC chip/TOF MS
data. One of these four isomers behaved unlike the other three
structurally very similar isomers. LNFP II (structure inset Figure
7A, note the terminal α-1,4-fucosylation) continually increased
from week 0 to week 13 (suggesting a lack of consumption by
intestinal bacteria). The other three isomers, LNFP I, III, and V,
all increased in fecal intensity during week 1 but decreased
dramatically during week 2 and stayed very low through week 13
(suggesting consumption). These isomers bear the α-1,2-fucosyl
and α-1,3-fucosyl residues.
Figure 7B demonstrates another group of isomers from Infant
A with an overall hexasaccharide structure with a common
monoisotopic mass of 1074.3963 (m/z 538, z = 2) and
composed of 4 hexose and 2 N-acetylglucosamine with at least
three linear or branched structures containing terminal β(1,3)-
and β(1,4)-galactose residues. All three isomers follow a similar
profile increasing in week 1 and decreasing thereafter (consistent
with consumption). The extracted ion chromatograms of these
isomers are shown in Figure 8. All isomers significantly decreased
by week 13 (Figure 8D). The results suggest little variation
between β-galactosidase linkage isomers in this infant.
Figure 9 demonstrates marked differences in individual fecal
HMO structures of Infant A over time, consistent with the
hypothesized highly selective nature of consumption of HMOs
by the intestinal bacteria. For example, four HMOs (MFLNH I,
MFLNH III, IFLNH I, and IFLNH III (MW 1220.4542)) are
present in the feces until week 2 but diminish rapidly by week 13
(concurrent with the bloom of bifidobacteria), suggesting
preferential consumption; meanwhile, isomer 4120a increases
at week 13, suggesting that the fecal microbes may be unable to
digest this structure (Figure 9A). Isomers DFLNHb, and
DFLNHc (MW 1366.512) both show a decrease concomitant
with the bloom of bifidobacteria at week 13; however, this
pattern is not seen with isomer DFLNHa (Figure 9B). Isomers
5130a, 5130b, F-LNO, and 5130c (MW 1585.5864) all
diminished at week 13, suggesting consumption (Figure 9C).
Isomers 5230a, 5230b, and DFLNnO II (MW 1731.6443)
demonstrate the pattern consistent with consumption, but
DFLNnO I is markedly increased, suggesting a lack of
consumption by the fecal microbes at 13 weeks (Figure 9D).
Isomer analyses of fecal HMOs for Infant B as quantified by
the H/D ratios using nano-HPLC chip/TOFMS data are shown
in Supporting Information Figures 1−3. Fecal profiles of Infant B
for lacto-N-fucopentaose isomers (MW 855.3220) are shown in
Supporting Information Figure 1A. The α-1,4-fucosylated LNFP
II increased slightly from week 0 to week 1 and then plateaued in
weeks 2−14 (5.7753 ± 0.3185), suggesting nonconsumption by
intestinal bacteria. The other three isomers, LNFP I, III, and V,
increased dramatically in fecal intensity during week 1 but
decreased in intensity at week 14, suggesting consumption at the
fecal profile shift to Bacteroides spp. at week 14.
Supporting Information Figure 1B shows fecal profiles of
another group of isomers withMW1074.3963. All three isomers,
LNH, LNnH, and p-LNH, show a decrease concomitant with the
bloom of bacteroides at week 14, suggesting consumption. The
extracted ion chromatograms of said isomers are shown in
Supporting Information Figure 2. All isomers increased from
week 0 to week 2 and then decreased in week 14, consistent with
consumption. Similar to Infant A, the results suggest little
variation between β-galactosidase linkage isomers in Infant B.
Other individual fecal HMO structures and isomers are shown
in Supporting Information Figure 3. For example, all five isomers
of MW 1220.4542 (4120a, MFLNH I, MFLNH III, IFLNH I,
and IFLNH III) decrease over time (Supporting Information
Figure 3A). Isomers DFLNH a, b, and c all show a decrease at
week 14 (Supporting Information Figure 3B). Isomers 5130a
and 5130c (MW 1585.5864) both show a decrease at week 14,
suggesting consumption, whereas 5130b and F-LNO increased
at week 14 (Supporting Information Figure 3C). Isomers 5230a
and DFLNnO I and II (MW 1731.6443) show a pattern
consistent with consumption, but 5230b is markedly increased,
suggesting a lack of consumption by the fecal microbes at 14
weeks (Supporting Information Figure 3D).
■ DISCUSSION
Rationale for Quantitation Method
Quantitation of milk oligosaccharides is complicated by the
different ionization properties of the different structures.
Suppression effects are observed when the sample is analyzed
as a mixture by mass spectrometry. For example, sialylated
oligosaccharides are often suppressed by neutral oligosaccharides
in the positive mode, whereas the reverse happens in the negative
mode.41 Separation of the oligosaccharides eliminates suppres-
sion effects; however, there are still slight variations in the
ionization of the individual structures. To minimize these effects,
Figure 8. LC−MS extracted ion chromatograms of m/z 538 ([M +
2H]2+, z = 2, M = 1074.3963) in the fecal HMO profile of Infant A using
nano-HLPC chip/TOFMS. Chromatograms at (A) week 0, (B) week 1,
(C) week 2, and (D) week 13. M = monoisotopic (neutral) mass.
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each compound was used as its own control. In addition, the
internal standards from the pooled milk sample contain more
structures than any individual specimen, allowing the analysis of
large biological diversity.
Fecal HMO Profiles Correlate with Changes in Bacterial
Population
The two infants studied were both healthy, breast-fed infants, but
the colonization of their intestinal tract differed remarkably. The
fecal microbiota of Infant A was initially dominated by
Streptococcus spp., whereas the gut microbiota of Infant B was
dominated by Escherichia spp. These bacteria are common
commensals of the birth canal and are not HMO consumers, i.e.,
do not have the genetic capability to produce the glycosidases
necessary to break down the linkages of HMO. The increase in
fecal HMOs in weeks 0−2 in both infants is consistent with the
hypothesized lack of HMO consumption during this period.
However, by week 13, Bifidobacterium spp. dominated in Infant
A, and levels of most fecal HMOs dropped dramatically. The
decline in HMO intensity is significantly negatively correlated to
Bifidobacteriales abundance and positively correlated with several
other bacteria, notably, Enterobacteriales and Bacillales. For Infant
Figure 9. H/D ratios of four isomeric groups of oligosaccharides in the fecal HMO profile of Infant A. H/D ratios were calculated using nano-HLPC
chip/TOF MS data. (A) Five isomers of m/z 611 ([M + 2H]2+, z = 2, M = 1220.4542, sixth bar from the left in each week in Figure 1A). (B) Three
isomers ofm/z 684 ([M + 2H]2+, z = 2, M = 1366.5121, seventh bar from the left in Figure 1A). (C) Four isomers ofm/z 794 ([M + 2H]2+, z = 2, M =
1585.5864, tenth bar from the left in Figure 1A). (D) Five isomers ofm/z 867 ([M+ 2H]2+, z = 2,M= 1731.6443, 11th bar from the left in Figure 1A).M
= monoisotopic (neutral) mass.
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B, Bacteroides spp. were dominant by week 14, at which time
levels of many fecal HMOs were decreased compared to those at
weeks 1 and 2.
The enrichment of Bifidobacterium spp. and Bacteroides spp. in
the gastrointestinal tract of infants has been previously
demonstrated.42 Moreover, metagenomic analysis has revealed
that this enrichment also corresponds with increased expression
of many genes involved in consumption of complex
oligosaccharides.43 We have previously shown in vitro that
Bacteroides are good consumers of HMOs40 and that B. infantis
can grow with HMOs as the sole carbon source.4 In spite of the
complexity of this ecological niche, the in vivo data here
presented match closely the in vitro results for the single species
analysis. These results further support the concept that one
function of HMOs is to selectively enrich a saccharolytic bacterial
consortium despite the variety of bacteria introduced into the
infant in the early days of life.
Enzymatic Activity: A Signature of the Gut Microbiota
Our method allows simultaneous analysis of up to 75 structurally
elucidated oligosaccharides and the monitoring of hundreds of
structures simultaneously.44 Profiles of human milk across 6
months of lactation show the constant delivery of HMOs with
minor fluctuation particularly for the smaller, more abundant
oligosaccharides (degree of polymerization < 7).38 This level of
detail allows the elucidation of gross glycosidic enzyme actions
by the microbiota, i.e., the consumption of known structures is an
indicator of the presence of specific active bacterial enzymes in
the gut.
The whole genome sequencing of B. infantis revealed a number
of exoglycosidases including galactosidases, fucosidases, and
sialidases.45,46 This high degree of enzymatic activity is not seen
in several other bifidobacterial species and in part explains the
dominance of the B. longum group in Infant A (B. infantis is a
member of the B. longum group).
Of particular interest is the catabolism of oligosaccharides
containing (α1,2)-fucose. The presence of 2′FL and other
(α1,2)-fucose-containing HMOs such as lacto-N-fucopentaose
(LNFP) indicates that the mother has at least one functional
fucosyl transferase (FUT2) allele and is therefore a secretor (i.e.,
able to express specific fucosylated structures in secretions such
as tears, milk, or saliva).19,47,48 In adults, secretor status is
associated with increased fecal bifidobacteria49 and with
alterations in susceptibility to viral and bacterial infections.23,50
The observation that these special fucosylated oligosaccharides
are preferentially consumed in healthy infants suggests the
hypothesis that certain bifidobacteria thrive in a milieu that
contains either milk from a secretor mom or intestinal secretions
from a secretor infant. This may have particular value to the
fragile premature infant where human milk is partially protective
against sepsis and necrotizing enterocolitis51 and nonsecretor
status may predispose to these common complications.52
Limitations of Present Study and Avenues for Future
Research
The analysis of fecal samples from two infants was designed as a
proof-of-concept exercise to demonstrate the potential utility of
analyzing the fecal microbiota and fecal glycomics in tandem.
The small sample size was helpful in generating hypotheses, but
future studies with larger sample sizes would be necessary to
confirm and replicate the findings.
Analysis of milk specimens from the mothers of these infants
would have been helpful to confirm consistent delivery of HMOs
over time (demonstrated in other mothers, but not in these two
cases). Inclusion of maternal dietary analysis and details
regarding the mothers’ health status (e.g., obesity, diabetes,
medications) would have been useful. The major strength of
these observations is the detailed analyses performed including
differentiation of isomers with differing patterns of possible
consumption by the intestinal microbes. Diagnostic testing of the
stool of infants, children, and adults for rapid determination of
secretor status or to identify patterns of HMOs or bacterial
enzymes suggestive of increased risk for necrotizing enterocolitis,
Clostridium difficile colitis, or inflammatory diseases of the gut
may be possible with approaches similar to those demonstrated
herein. Such an approach may be of value in high-risk
populations.
■ CONCLUSIONS
This proof-of-concept study combines glycomics and genomics
to monitor the changes in HMOs and gut microbiota in
breastfeeding infants. The observed changes over time in two
infants suggest the need for more extensive studies of a larger
cohort to test the hypothesis that HMOs enrich a cognate
oligosaccharide-consuming microbial population in the infant
gut by orchestrating a shift in the infant fecal microbiota from a
nonsaccharolytic population dominated by commensals of the
birth canal to a population dominated by saccharolytic microbes
concurrent with a decrease in fecal HMO intensities. Further
studies in nonhuman primates and other mammals would be
valuable to determine whether feedback evolutionary mecha-
nisms link the infant gut and maternal milk oligosaccharide
production.
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